13 results about "Quinazoline derivatives" patented technology

This invention belongs to the field of organic synthetic chemistry technology, specifically relating to a selenium-based indoloquinazoline derivative, its preparation method, and its application, comprising: in an organic solvent, using aromatic amine compounds, malononitrile, and diselenoether as raw materials, in the presence of a palladium catalyst and an organic base, at 90°C... o The reaction was carried out under C conditions with stirring to obtain a selenyl indoline quinazoline derivative. This method features mild reaction conditions, simple operation, high yield, and good functional group compatibility, conforming to the principles of green chemistry. Furthermore, the selenyl indoline quinazoline derivative provided by this invention exhibits good inhibitory activity against Plasmodium, providing a drug lead compound for the development of novel antimalarial drugs and holding significant importance for the prevention and / or treatment of malaria.

The present application relates to compounds of formula (A) that inhibit the growth of cancers that express G12D mutant Ras proteins. The molecules of the specification are thus indicated for use in the treatment of cancer that express G12D mutant Ras protein.

Use of a quinazoline compound and a third-generation epidermal growth factor receptor (EGFR) inhibitor in a combined drug for treating non-small cell lung cancer. The quinazoline compound comprises at least one of a quinazoline derivative represented by formula (I), a salt thereof, a solvate thereof, a hydrate thereof, and a polymorph thereof.

The present application relates to a quinazoline derivative of general formula (I) or stereoisomer, pharmaceutically acceptable salt, solvate, or tautomer, which can selectively inhibit CDK9 and / or TNIK, and has good enzymatic and cellular activity.

The present application relates to quinazoline derivatives, salts thereof, and pharmaceutical compositions comprising the same as an effective ingredient, which can exhibit a preventive or therapeutic effect on cancer by inhibiting MASTL activity, and in particular, can exhibit an effective anticancer effect in cancer in which MASTL is overexpressed, such as breast cancer.

This application discloses trisubstituted quinazoline derivatives, their acid addition salts, pharmaceutical compositions thereof, and uses. Specifically, the trisubstituted quinazoline derivatives are (E)-4-(dimethylamino)-N-(4-((4-(4-fluoro-phenoxy)phenyl)amino)-7-ethoxyquinazoline-6-yl)but-2-enamides. This application also discloses (E)-4-(dimethylamino)-N-(4-((4-(4-fluoro-phenoxy)phenyl)amino)-7-ethoxyquinazoline-6-yl)but-2-enamide acid addition salts, their solvates or hydrates, or pharmaceutical compositions thereof. The substances disclosed in this application can be used for the prevention, inhibition, or treatment of cancer.

The present disclosure is directed to tetrahydroquinazoline derivatives of Formula (I) and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naive cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).

This disclosure relates to tetrahydroquinazoline derivatives represented by Formula I, and their use for selectively killing HIV-infected GAG-POL-expressing cells without cytotoxicity to HIV-naive cells, and for treating or preventing HIV infection, or for treating, preventing or delaying the onset or progression of AIDS or AIDS-related syndromes (ARC). [Formula 1] TIFF2026516541000123.tif46141

The present disclosure relates to quinazoline derivative compounds and medicinal uses thereof. Specifically, the present disclosure provides compounds capable of treating or preventing c-KIT or PDGFR-related diseases by inhibiting c-KIT or PDGFR.

The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

This invention relates to the field of pharmaceutical synthesis technology, specifically disclosing a 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative and its general structural formula; it also discloses the preparation method and application of this derivative. This 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative exhibits good inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) and can be used to prevent and treat diseases caused by MRSA infection. Preferably, these diseases include, but are not limited to, pneumonia, urinary tract infections, bacteremia, sepsis, and suppurative arthritis caused by MRSA in humans and animals. The beneficial effects of this invention are: the 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative of this invention is obtained through a four-step reaction, the preparation method is simple, and the reaction conditions are mild; it has good inhibitory and bactericidal activity against MRSA and can be used to prevent and treat diseases caused by MRSA infection.